ClinicaliQ Trial Snapshot
- Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors — Recruiting • Phase I • Oncology • NCT05797168.
- What is being tested: AZD5335, an antibody-drug conjugate, is being evaluated both as a standalone treatment and combined with established anti-cancer agents to assess safety, tolerability, and anti-tumour efficacy in patients with advanced solid tumours.
- Patient eligibility overview: This early-phase trial (Phase I/IIa) recruits patients with advanced solid tumours; specific inclusion criteria (performance status, organ function, prior treatments) would be detailed in the full protocol to ensure participant safety during initial human testing.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
This research is designed to determine if experimental treatment with Antibody-drug conjugate, AZD5335, alone, or in combination with anti-cancer agents is safe, tolerable, and has anti-cancer activity in patients with advanced tumors
Eligibility Snapshot
- Core Inclusion Criteria: * Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the ICF and in this protocol. * Provision of signed and dated written Optional Genetic Research Information informed consent prior to collection of samples for optional genetic research that supports Genomic Initiative. Participants who do not provide informed consent for Optional Genetic Research may still be enrolled in the study. * Participant must be ≥ 18 years at the time of signing the informed consent. * Willing to provide adequate archival and/or baseline tumor sample as applicable per module-specific criteria. * For participants who have previously received targeted therapies such as ADCs, a fresh baseline biopsy will be required unless the most recent archival tissue sample was collected after receipt of such treatment. * Eastern Cooperative Oncology Group Performance Status of 0 or 1. * Participants with advanced solid tumors must have received prior adequate therapy in accordance with local practice for their tumor type and stage of disease, or, in the opinion of the Investigator, a clinical trial is the best option for the next treatment based on response and/or tolerability to prior therapy. Participants with contraindications or who…
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.